NDLI: Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Kishore, Meena Kumari Kamal Thanusubramanian, Harish Shenoy, Smita Sashidharan, Nithin
Description	Country affiliation: India Author Affiliation: Sashidharan N ( Assistant Professor, Department of Pharmacology, Srinivas Institute of Medical Sciences , Mukka, Mangalore, Karnataka, India .); Shenoy S ( Additional Professor, Department of Pharmacology, Kasturba Medical College, Manipal University , Manipal, Karnataka, India .); Kishore MK ( Associate Professor, Department of Pharmacology, Kasturba Medical College, Manipal University , Manipal, Karnataka, India .); Thanusubramanian H ( Tutor, Department of Pharmacology, Kasturba Medical College, Manipal University , Manipal, Karnataka, India.)
Abstract	BACKGROUND: Multiple myeloma accounts for 1% of all neoplastic disorders and 10% of all haematological malignancies. Drugs like thalidomide, lenalidomide and bortezomib have emerged as active drugs in the treatment of multiple myeloma.There are few studies which have compared thalidomide-dexamethasone (thal/dex) and lenalidomide-dexamethasone (len/dex) in the treatment of multiple myeloma in Indian scenario. AIM: To compare the efficacy and the adverse events observed with thalidomide-dexamethasone and lenalidomide-dexamethasone in the treatment of newly diagnosed cases of multiple myeloma. SETTINGS AND DESIGN: Observational Study conducted in tertiary care centre. MATERIALS AND METHODS: The case record files of patients from the year January 2006 to July 2011 with diagnosis of multiple myeloma were studied. STATISTICAL ANALYSIS: Primarily Descriptive. RESULTS: There was no significant difference between thal/dex and len/dex treatment groups with respect to efficacy and safety in our study. CONCLUSION: Studies with larger sample size and a longer follow up to compare efficacy and safety of thal/dex and len/dex in treatment of multiple myeloma are required to be carried out to provide significant results.
ISSN	2249782X
e-ISSN	0973709X
DOI	10.7860/JCDR/2015/11798.5895
Journal	JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
Issue Number	5
Volume Number	9
Language	English
Publisher	Dr. Hemant Jain (for Premchand Shantidevi Research Foundation)
Publisher Date	2015-05-01
Publisher Place	India
Access Restriction	Open
Subject Keyword	Discipline Multidisciplinary
Content Type	Text
Resource Type	Article
Subject	Clinical Biochemistry

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in